SCHEMBL25552001

SCHEMBL25552001

COC(=O)c1nccc(-c2ccc(F)cc2C)n1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMO O15229 7/20 0.54
CDK9 P50750 4/20 0.44
CCNT1 O60563 3/20 0.44
ALPL P05186 2/20 0.42
BRD4 O60885 1/20 0.41
OXTR P30559 1/20 0.40
AVPR1A P37288 1/20 0.40
CYP46A1 Q9Y6A2 1/20 0.40
WDR5 P61964 1/20 0.40
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
CTSA P10619 1/20 0.39
POLQ O75417 1/20 0.38
ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037065 1.00 KMO (0.54) KMOCDK9CCNT1ALPLBRD4
SCHEMBL25551996 0.85 KMO (0.74) KMOCDK9CCNT1
SCHEMBL25560110 0.85 KMO (0.58) KMOCDK9CCNT1BRD4OXTR
SCHEMBL30037008 0.85 KMO (0.74) KMOCDK9CCNT1
SCHEMBL25560120 0.82 KMO (0.54) KMOCDK9CCNT1BRD4WDR5
SCHEMBL12538183 0.79 NPC1 (0.57) KMONPC1CASP3RAB9ASMN1; SMN2
SCHEMBL25731962 0.77 KMO (0.46) KMOCDK9CCNT1BRD4WDR5
SCHEMBL25560102 0.75 KMO (0.44) KMOCDK9CCNT1BRD4OXTR
SCHEMBL931505 0.75 OXTR (0.59) ALPLOXTRAVPR1ANPC1RAB9A
SCHEMBL12615933 0.74 NPC1 (0.51) KMONPC1CASP3RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 KMO 3071/4885CDK9 588/4885CCNT1 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.